XBiotech Inc. (XBIT): Shareholders' Equity
$140.35M
As of 2025-12-31
$128.46M
As of 2026-06-30
-16.4%
3-year compound annual growth
-16.6%
5-year compound annual growth
+3.1%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $140.35M | -23.0% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $182.27M | -16.7% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $218.85M | -9.0% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $240.40M | -10.8% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $269.38M | -22.7% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $348.64M | -53.9% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $755.63M | n/m | 2022-03-15, Balance as of period end |
| 2018-12-31 | $41.40M | -31.2% | 2021-03-16, Balance as of period end |
| 2017-12-31 | $60.16M | +1.9% | 2020-03-16, Balance as of period end |
| 2016-12-31 | $59.06M | -42.7% | 2019-03-15, Balance as of period end |
| 2015-12-31 | $103.05M | +74.6% | 2018-03-16, Balance as of period end |
| 2014-12-31 | $59.03M | +477.1% | 2017-03-16, Balance as of period end |
| 2013-12-31 | $10.23M | n/a | 2016-04-15, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| XBiotech Inc. (XBIT) | 2025-12-31 | $140.35M | -23.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $136.31M | +159.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $130.66M | +91.5% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $99.01M | n/m |
| Veradermics, Inc (MANE) | 2025-12-31 | -$121.01M | n/m |
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $78.08M | -54.6% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $35.27M | +100.4% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $20.91M | -45.7% |
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $98.65M | -34.5% |
Compare XBIT, WHWK, OVID, CTMX side by side · Screen every company in Pharmaceutical Preparations ↗